Navitoclax (ABT-263)

For research use only. Not for use in humans.

目录号：S1001

CAS No. 923564-51-6

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3285.53	现货
5mg	RMB 975.71	现货
10mg	RMB 1631.61	现货
25mg	RMB 3016.58	现货
100mg	RMB 7950.36	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Navitoclax (ABT-263)发表文献237篇：

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):54

PubMed: 33423045 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):121

PubMed: 33495462 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(2)E752

PubMed: 33451095 ( click the link to review the publication )

Transl Oncol, 2021, 14(5):101048

PubMed: 33667892 ( click the link to review the publication )

BMC Complement Med Ther, 2021, 21(1):88

PubMed: 33750370 ( click the link to review the publication )

PLoS Comput Biol, 2021, 17(2):e1008630

PubMed: 33617523 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1134

PubMed: 33602934 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1281

PubMed: 33627663 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )
Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33393

PubMed: 33186476 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Med Chem, 2020, 63(22):13733-13744

PubMed: 33197310 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2551

PubMed: 32911681 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):130

PubMed: 33239070 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):854

PubMed: 33056980 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(11)E1143

PubMed: 33218059 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0586.2020

PubMed: 33288732 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )
Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30635-2

PubMed: 33259900 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, S0360-3016(20)34731-3

PubMed: 33385497 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-5

PubMed: 32627634 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2137

PubMed: 32752193 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2298

PubMed: 32824203 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Trop Life Sci Res, 2020, 31(3):1-13

PubMed: 33214852 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107830

PubMed: 32610131 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.201900218R

PubMed: 32619061 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )
EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )
Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Oncogene, 2018, 37(22):2936-2952

PubMed: 29520102 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )
Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Aging Cell, 2017, 16(4):693-703

PubMed: 28401730 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )
Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Tumour Biol, 2017, 39(5):1010428317699120

PubMed: 28459212 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )
Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82013-82027

PubMed: 27852038 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34453-71

PubMed: 27144341 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2959-70

PubMed: 26096065 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2034

PubMed: 26720343 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )
Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26059440 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Haematologica, 2013,

PubMed: 23850807 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

J Neurosci, 2013, 33(12):5195-207

PubMed: 23516285 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4518-26

PubMed: 21546570 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

靶点

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，K_i分别为0.5, 1和1 nM。^[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
FL5.12	NEH4dZREgXSxdH;4bYNqfHliYYPzZZk>	M2\nb\|I1KGh?	M{C4PGVEPTBiPTCwMlAxPDJizszN	M2raXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
FL5.12	NHXaRZVEgXSxdH;4bYNqfHliYYPzZZk>	MonnNlQhcA>?	MlfoSWM2OCB;IECuNFA2QSEQvF2=	M1ntUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
RS4:11	MUfBdI9xfG:\|aYOgZZN{[Xl?	MlHXOkBp	MnfHSWM2OCB;IECuNFE1KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6MUW2O{c,OjR6OEG1Olc9N2F-
FDC-P1	M1TpWmJEVC1{IHnubIljcXSrb36gZZN{[Xl?	NXvwSpVQOjRiaB?=	M1XycmlEPTBiPTCwMlAyPSEQvF2=	NYPTdllTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2PjdpPkK0PFgyPTZ5PD;hQi=>
NCI-H1963	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=	NGfIUGI1KGSjeYO=	M1:xOmlEPTBiPTCwMlAzPjZizszN	NVnC[VhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFgzQThpPkKzOFQ5Ojl6PD;hQi=>
NCI-H187	MnHlR5l1d3SxeHnjbZR6KGG\|c3H5	MlO4OEBl[Xm\|	MVTJR\|UxKD1iMD6wN\|g1KM7:TR?=	NVzu[oZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFgzQThpPkKzOFQ5Ojl6PD;hQi=>
NCI-H1417	M4fKb2N6fG:2b4jpZ4l1gSCjc4PhfS=>	Ml3ZOEBl[Xm\|	MoT2TWM2OCB;IECuNFU1OiEQvF2=	NGjQWow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
FDC-P1	NIrGfJFDS0xveFygbY5pcWKrdHnvckBie3OjeR?=	M{Ta[FI1KGh?	MofZTWM2OCB;IECuNFYh\|ryP	M3TEeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEixOVY4Lz5{NEi4NVU3PzxxYU6=
NCI-H146	M{fPVWN6fG:2b4jpZ4l1gSCjc4PhfS=>	M{PVNFQ5KGh?	NYT1[nl1TUN3MDC9JFAvODh4NzFOwG0>	NWW4VXJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
RS4:11	NX31T25OSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NIXLNpNGSzVyIE2gNE4yOTJizszN	MnrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7Mk[yOFcoRjJ6OUK2NlQ4RC:jPh?=
MOLT4	NXjsOJF[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MVLFR\|UxKD1iMD6zNFMh\|ryP	NUnjU4puRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NlYzPDdpPkK4PVI3OjR5PD;hQi=>
EoL-1-cell	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVjJR\|UxRTBwMEC2Olkh\|ryP	MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MV-4-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkDoTWM2OD1yLkCxOVg3KM7:TR?=	MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NKM-1	M4PRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYfJR\|UxRTBwMEG2PVkh\|ryP	M1rZV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ML-2	M2e2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2ftSGlEPTB;MD6wNVk5OyEQvF2=	NE\NTI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BV-173	M1yxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWTJR\|UxRTBwMEKzNVQh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RS4-11	NFLEb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH:3TYFKSzVyPUCuNFI2QDdizszN	MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HL-60	M3iwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWHJR\|UxRTBwMEK5NFgh\|ryP	MmLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KY821	NF\1[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYXJR\|UxRTBwMEK5O\|Uh\|ryP	M{jYUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ECC10	NWLX[\|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEXvdVJKSzVyPUCuNFM4QTJizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H720	MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnO4TWM2OD1yLkC0NFEyKM7:TR?=	NWTobmNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
QIMR-WIL	NI\PWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVzCfHprUUN3ME2wMlA1Ojh5IN88US=>	M1H2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KG-1	NUGzblJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{e1T2lEPTB;MD6wOFQ5PiEQvF2=	NH;UUoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TGW	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHfTcndKSzVyPUCuNFQ3OzNizszN	M2nwSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ATN-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYnJR\|UxRTBwMES3N\|Mh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RH-18	NITXTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlTRTWM2OD1yLkC2NFQ5KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EW-18	NEPq[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn;hTWM2OD1yLkC2PFQyKM7:TR?=	NYTYNWUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB17	NYTtdVJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWnnPZRRUUN3ME2wMlA4OTJ2IN88US=>	NHHwOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-NEP-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX30TlZDUUN3ME2wMlA4OjF\|IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
P12-ICHIKAWA	NFK3[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUTJR\|UxRTBwMEe3O\|gh\|ryP	M3T5dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KARPAS-45	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWTJR\|UxRTBwMEe4NVUh\|ryP	NImyOZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EW-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3HXPWlEPTB;MD6wPFA2OyEQvF2=	MmDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NB13	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYjyWXpjUUN3ME2wMlA5OjB\|IN88US=>	NH:3NZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H209	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mmr0TWM2OD1yLkC4O\|A1KM7:TR?=	NYHBVGJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1092	M3;IcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYDnVYs5UUN3ME2wMlExOjd3IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NH-12	NID2dWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH;PeJpKSzVyPUCuNVA4PDRizszN	NF;JXFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
697	M125VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NE\k[VRKSzVyPUCuNVA5OzlizszN	MmG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KE-37	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2ixSWlEPTB;MD6xNVM4KM7:TR?=	NVHDOmk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MOLT-4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVfZfFdQUUN3ME2wMlE2OTZ7IN88US=>	NWLKbo06RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CHP-134	M36xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX3JR\|UxRTBwMU[zNFYh\|ryP	NWHnT2pzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
D-283MED	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFH4UZRKSzVyPUCuNVc3QDZizszN	NWD0W3UxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LU-135	M2rFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH35WpBKSzVyPUCuNVg2PTJizszN	NUDNcYFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LU-134-A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm\0TWM2OD1yLkG4OlcyKM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EM-2	NEWz[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfsUVVnUUN3ME2wMlE6QTF6IN88US=>	NHTudnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LU-139	M3;3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXv6[lNCUUN3ME2wMlIxPDl6IN88US=>	M{ixfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ALL-PO	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3fhXWlEPTB;MD6yNVk5QCEQvF2=	NGHubZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NB12	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlTXTWM2OD1yLkKzNVE2KM7:TR?=	M1Hae\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KP-N-YN	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWHJR\|UxRTBwMkO1O\|Mh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
BEN	M1j4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIH5XHZKSzVyPUCuNlM6PjhizszN	NWjYRllERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC1569	M3znUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWXJR\|UxRTBwMkWxNFYh\|ryP	NUXB[W9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HuO9	NYDQRnBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXjKdGp2UUN3ME2wMlI3PzF3IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
WM-115	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGP3WlBKSzVyPUCuNlc4OzhizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CCRF-CEM	NVPER4txT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYjmRmtZUUN3ME2wMlM{PTJ7IN88US=>	NFvKbIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
IST-SL1	M2nIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEXjem5KSzVyPUCuN\|U{PDNizszN	NGnjdpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BE-13	NGrjWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXrJR\|UxRTBwM{[0OVkh\|ryP	NICwW3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COR-L88	M1\XO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NELITmdKSzVyPUCuN\|Y2PCEQvF2=	M3XaOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
DOHH-2	M1HpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3zsOGlEPTB;MD60NVAzOyEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
A704	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGjpe\|lKSzVyPUCuOFI3PyEQvF2=	NHTNfow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KNS-81-FD	NYW4XnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2r6ZWlEPTB;MD60OFAyPyEQvF2=	Mn73QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RPMI-8226	NI\5[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmTLTWM2OD1yLkS1OlUzKM7:TR?=	M1XjSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TGBC24TKB	M4[1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHu3[3lKSzVyPUCuOFU4PzhizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1304	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHjCU\|BKSzVyPUCuOFYyPTdizszN	MlT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MOLT-13	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2e1dGlEPTB;MD60OlYyOyEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EW-22	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEHifGdKSzVyPUCuOFY3PzFizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MS-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1;pRmlEPTB;MD60Olk{OyEQvF2=	MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RMG-I	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYfBe4hwUUN3ME2wMlQ6PDZ2IN88US=>	NUHYUJhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NTERA-S-cl-D1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHLHWZVKSzVyPUCuOVAxOTlizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1048	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFnvfWVKSzVyPUCuOVA6PTNizszN	M{TYZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW1417	M3OzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV7qe4lvUUN3ME2wMlU2PDN6IN88US=>	NI\IbFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DB	NY\6WFhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3PTWM2OD1yLkW3NFgh\|ryP	MljXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MEG-01	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV3JR\|UxRTBwNUizNkDPxE1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EW-13	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mon6TWM2OD1yLkW4N\|QyKM7:TR?=	NVjLd2dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LAMA-84	MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\5fGlEPTB;MD61PVIxPyEQvF2=	NGi3NGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
J-RT3-T3-5	NWnoXlVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;uUGlEPTB;MD62NFgxQCEQvF2=	M{\yVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MOLT-16	NWniUIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVL5eWp3UUN3ME2wMlY2OjZ2IN88US=>	M2TUVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
DU-4475	M{nD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3hN25KSzVyPUCuOlU1OjdizszN	M{nYNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HAL-01	NYDjSoptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIDoW3pKSzVyPUCuO\|I2PDlizszN	M3XLdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RD	NX3qUIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoD3TWM2OD1yLke1PFk6KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OAW-28	NGHXbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPxcIJKSzVyPUCuO\|g{PyEQvF2=	NWfmS4V3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC38	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUXJR\|UxRTBwOECxPUDPxE1?	M3H2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NMC-G1	NVXkS25bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVL1bldnUUN3ME2wMlgyOTJzIN88US=>	M1:1VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-16	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3;KT2lEPTB;MD64NVMzQCEQvF2=	M3myWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
DU-145	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkHFTWM2OD1yLki5PVI{KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HPAF-II	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWDJWIJKUUN3ME2wMlkzPjJ6IN88US=>	NHzmemM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
A427	NIfHW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYjkVZpOUUN3ME2wMlk{ODJ{IN88US=>	NYi2foxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PA-1	NXPKXGlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml7mTWM2OD1yLkm1OlQzKM7:TR?=	M37tTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
OAW-42	NV3SSYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUP1[VZRUUN3ME2wMlk3OTR4IN88US=>	NELBSVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
L-428	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NInOPGVKSzVyPUGuNFEzPSEQvF2=	M1raRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-824	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4C1UmlEPTB;MT6wNVcxQCEQvF2=	MmTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
P30-OHK	NFPpeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVr3fnJOUUN3ME2xMlA1Pjh6IN88US=>	NIrX[Zo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2170	M1m2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{njO2lEPTB;MT6wOlI{KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC2998	M4fVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NITHT3BKSzVyPUGuNFcyOzVizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB14	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHETWM2OD1zLkGzO\|Q5KM7:TR?=	MlXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TGBC1TKB	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn3DTWM2OD1zLkG0NVUzKM7:TR?=	NIrBeXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KP-N-YS	M{HWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{O0dWlEPTB;MT6xOlI{PiEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CAL-120	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIHTPWJKSzVyPUGuNVY1OjlizszN	Mn\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SBC-1	M{DyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV3JR\|UxRTFwMUmwOVMh\|ryP	MnzHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
C32	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mo\CTWM2OD1zLkG5NFg5KM7:TR?=	M{niTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC2157	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYK3OpNGUUN3ME2xMlE6PDl2IN88US=>	NFm2[XQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COLO-792	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVvJR\|UxRTFwMkCwO\|Eh\|ryP	NGjJ[HY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ES7	NWDjPYtWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYO5bZpJUUN3ME2xMlI4QTVzIN88US=>	NGXSfHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HEL	MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlvSTWM2OD1zLkOxNFI6KM7:TR?=	NHLiSYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ES4	NXHHenZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYHJR\|UxRTFwM{S5PVgh\|ryP	MlvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHRTWM2OD1zLkO2OVU2KM7:TR?=	NIPvSHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MDA-MB-415	NIqzcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFe2SYFKSzVyPUGuN\|g5PSEQvF2=	NWLlZmRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2342	NXTseGVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4rweWlEPTB;MT60NFI3QSEQvF2=	NXLQOVJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB69	M1zhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYHJR\|UxRTFwNE[yO\|Eh\|ryP	NXP1ZZhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
D-247MG	NIC3UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF3FWIxKSzVyPUGuOVEyOjJizszN	NGDMWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SCC-4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2frS2lEPTB;MT61PVg5PyEQvF2=	M2nEd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HuH-7	M3fS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUfQOZAyUUN3ME2xMlY4Ojl\|IN88US=>	MmTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
A388	NI\wXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2TPWGlEPTB;MT62PFczPCEQvF2=	M1qzTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Calu-3	NH;kZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{TobGlEPTB;MT63NFY6PyEQvF2=	MkX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1648	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{WxTGlEPTB;MT63NVQyQCEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2052	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYL1WFh6UUN3ME2xMlczOjBzIN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXLJR\|UxRTFwN{O2OVYh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DEL	M{\oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1eyOWlEPTB;MT63OFY6OiEQvF2=	NIjFOFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SNU-423	NILYZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF\nRXlKSzVyPUGuO\|gyPTdizszN	NULHRnkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COR-L23	NVLSSot1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXr0WGxpUUN3ME2xMlc6QDd2IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OMC-1	M3i2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVnad3g6UUN3ME2xMlg3ODF4IN88US=>	MmrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWPXW4hHUUN3ME2xMlk2PjV5IN88US=>	MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HSC-3	NWfM[WJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4e4O2lEPTB;MT65OlM3PSEQvF2=	M{jJb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MLMA	NHH3T3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUfnUHg5UUN3ME2xMlk3Pjd5IN88US=>	MojFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RCM-1	NFu5VpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3PncGlEPTB;Mj6wNFM6QSEQvF2=	NFX1VYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MFE-280	NX2yXJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVvJR\|UxRTJwMEK4OFgh\|ryP	NUOzcXVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES8	NGTSV\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEXtNIhKSzVyPUKuNlU1PzFizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TE-11	NE\1WZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUTTXFQ4UUN3ME2yMlI6PDd\|IN88US=>	MlewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HuO-3N1	M{LNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH;TVWtKSzVyPUKuOFg4QCEQvF2=	MlrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkPjTWM2OD1{LkWxNVU5KM7:TR?=	NUC0NYZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TGBC11TKB	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NETocG5KSzVyPUKuOVc3QDFizszN	NYXZcVIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HOP-92	M2TvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mof0TWM2OD1{LkW4O\|Q{KM7:TR?=	MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
IGR-1	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXzJR\|UxRTJwNkKwN\|Uh\|ryP	NEX1elc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GOTO	M3iyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUjPT2dFUUN3ME2yMlY2Ozd5IN88US=>	M1fUflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1650	MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3rocGlEPTB;Mj63NlIyPSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1581	NFXQfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWPJR\|UxRTJwN{m2PFEh\|ryP	NXHQcGV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2405	MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mm\QTWM2OD1{LkiyO\|gzKM7:TR?=	M{\rRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
U-118-MG	NYC2cGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUPJR\|UxRTJwOU[0PVEh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DoTc2-4510	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF[0c\|BKSzVyPUOuNFE1OTdizszN	NITvfJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H596	M{KwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3u3XmlEPTB;Mz6wOFk6PyEQvF2=	M2\a[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MPP-89	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYf0[2dTUUN3ME2zMlA2PjZ4IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
GCIY	NF23[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXixWYVNUUN3ME2zMlIxPDlzIN88US=>	M{fJ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW626	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\qTWM2OD1\|LkK0OVQ{KM7:TR?=	NH7MXlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OCI-AML2	M1\XOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVjUPIVCUUN3ME2zMlMyOjd{IN88US=>	NUW2fINTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NBsusSR	NVXpWpJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWDJR\|UxRTNwM{S5N\|gh\|ryP	Mnr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
AN3-CA	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY\JR\|UxRTNwNESyN\|gh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EFM-19	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\uXlRKSzVyPUOuOFg{OzlizszN	MkTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RVH-421	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4TrVWlEPTB;Mz61Olg4PyEQvF2=	Mo\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
5637	M1W3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MY\JR\|UxRTNwNkGxNFMh\|ryP	NHX5XZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
PANC-08-13	MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVT3b2w5UUN3ME2zMlY{PDd{IN88US=>	MonkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
H9	NEXBNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWS0V2g{UUN3ME2zMlY4OTR2IN88US=>	MmLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KARPAS-299	NGDK[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV\lNWtsUUN3ME2zMlY4OzZzIN88US=>	MlH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TE-5	NGrTdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLYNlFKSzVyPUOuO\|A4ODlizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NOS-1	NG\5dHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXntTlFEUUN3ME2zMlc6QDN2IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HH	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV;JR\|UxRTNwOEO4Olgh\|ryP	M2m3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
769-P	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV;JR\|UxRTNwOEm1NUDPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CHP-212	NWO5b3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUTJR\|UxRTNwOUK1OFkh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H82	Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkHJTWM2OD1\|Lkm1PVM3KM7:TR?=	NGjnS4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
Mo-T	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NInqRVdKSzVyPUSuNFQ{OTJizszN	NEPWSXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BB65-RCC	NUnyUWNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEHYTndKSzVyPUSuNFQ{QTlizszN	NV60UIxLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW1990	NIO2dVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVrFOI1IUUN3ME20MlA2QTB6IN88US=>	M{myflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LK-2	NV6xXWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmqyTWM2OD12LkGxNlk{KM7:TR?=	NY\XToNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES5	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVqzeWdqUUN3ME20MlE{QTh3IN88US=>	MmTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
JVM-3	M2W4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnvuTWM2OD12LkG4NlIzKM7:TR?=	NW[3UlRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RPMI-7951	NIHDd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4HXTGlEPTB;ND6yNlQyOyEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Calu-6	NEjCNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUDJR\|UxRTRwMke4PFEh\|ryP	MmX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LC-2-ad	M{fmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoLITWM2OD12LkK5OVY5KM7:TR?=	M{nLXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW954	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4LLRWlEPTB;ND6yPVY3KM7:TR?=	NGDkXnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
H-EMC-SS	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXTJR\|UxRTRwM{G4N\|Eh\|ryP	M{O4cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ES3	NUPYdVJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGHleGlKSzVyPUSuN\|U1PDFizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
no-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mk\OTWM2OD12LkO1OVU1KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LAN-6	NH\pVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXTJR\|UxRTRwNEWxPFkh\|ryP	MoH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
FTC-133	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH;FS\|FKSzVyPUSuOVM6PSEQvF2=	NEPmd5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
8505C	NVHlN3NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEfKfW1KSzVyPUSuOVQzOyEQvF2=	NEjq[ZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW620	NIHx[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUTydHRuUUN3ME20MlU4ODV5IN88US=>	M3;nV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BCPAP	NVrJOmxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3fJ[WlEPTB;ND62N\|Q5OSEQvF2=	M3TD[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-LU-1	NX\ITY97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGDT[\|BKSzVyPUSuOlYxQDlizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1623	M4O1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NITsWllKSzVyPUSuO\|AzOjhizszN	M1;DVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
C2BBe1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIfQO2JKSzVyPUSuO\|QxODhizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
GP5d	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{fIZ2lEPTB;ND63PFM5QCEQvF2=	M3S0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB6	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWXEU29OUUN3ME20Mlg3OjB2IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MDA-MB-157	M4TubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVjJR\|UxRTRwOEi3OkDPxE1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
UMC-11	M2PaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFr6e2NKSzVyPUSuPFg6PjRizszN	M1G4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC1419	NFnxc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVrsNIptUUN3ME20MlkxODZ\|IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2029	NYTKbXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXHJR\|UxRTRwOUSxPFUh\|ryP	M4D1bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LXF-289	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVHJR\|UxRTVwMEO3NVkh\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KINGS-1	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NE\QO5pKSzVyPUWuNFc4PDRizszN	M2LoelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HD-MY-Z	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\BS45KSzVyPUWuNlM6PjlizszN	NWjo[4dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ESS-1	NHLwXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUf3SJZYUUN3ME21MlI2PTl5IN88US=>	MknhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
GI-1	NF:3eHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHzpRphKSzVyPUWuNlc6OjZizszN	NGfMZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RPMI-2650	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIjSUZlKSzVyPUWuN\|YyPiEQvF2=	NGe4fnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
IA-LM	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{LHcWlEPTB;NT6zPVg4OSEQvF2=	NGP6d2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KP-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFTzUm1KSzVyPUWuOFY{OzRizszN	NGXTemg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
G-402	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4rkPWlEPTB;NT61NVg3PSEQvF2=	NGfZXmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OS-RC-2	NF3vW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGrZZZFKSzVyPUWuOVI3ODRizszN	Mnj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1155	NX\KVHF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXvCZlRFUUN3ME21MlU1QTV3IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OE19	NVe2[JBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUjJR\|UxRTVwNki2NlQh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
U-2-OS	M1zmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUDhbWVoUUN3ME21Mlg6ODF\|IN88US=>	MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SCC-15	M2DhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXXJR\|UxRTVwOUO2OlIh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H630	NHj0WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV3yOYk6UUN3ME21Mlk6PDB2IN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
PFSK-1	NEfsPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVHiNHE4UUN3ME22MlA2OjV7IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1770	MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoL2TWM2OD14LkKwPFc1KM7:TR?=	NWnxZlRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-MEL-3	M4rvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkDWTWM2OD14LkSyPVE2KM7:TR?=	NFTxcIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LB1047-RCC	M4Llemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIjwUGRKSzVyPU[uOFc3OjVizszN	Mnf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H446	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHXCb2dKSzVyPU[uOlI6OjVizszN	NHjT[mY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW780	NUHsbVAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2r3T2lEPTB;Nj63NFE5PSEQvF2=	NWDBdVRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NEC8	NIm2WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFf3TmFKSzVyPU[uO\|Y3OyEQvF2=	M2DMS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NOMO-1	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHrRSolKSzVyPU[uO\|gyOTFizszN	NFG5T4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COLO-668	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYPJR\|UxRTZwOESzPFch\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MC116	NIPhOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUPJR\|UxRTZwOUO4PVch\|ryP	M1TXRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC1937	M1[3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXfx[pRDUUN3ME22Mlk6OjVzIN88US=>	M{\jRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-N87	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4PYcGlEPTB;Nz6xPVI6OyEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
COLO-320-HSR	M{DUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3JXlhKSzVyPUeuNlI4OzhizszN	M2fsTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC1806	M{fSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmHrTWM2OD15LkK2NFQ1KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OVCAR-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{D2NGlEPTB;Nz6zN\|A{QCEQvF2=	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NUGC-3	M2jlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFzRSoJKSzVyPUeuN\|k3QTRizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1783	NV;xbVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3y2TGlEPTB;Nz60N\|E4PSEQvF2=	NGSwbmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GCT	NFPtPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUXmdnZnUUN3ME23MlU3QTB4IN88US=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2126	M1rsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml\BTWM2OD15LkezOlI2KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MEL-HO	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXnJR\|UxRTdwN{ewOVQh\|ryP	NHf6T3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAPAN-1	NWS2b5VvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVfpe29CUUN3ME23Mlc4OzV5IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW756	M1LYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVnzNGhkUUN3ME23Mlc5OzN\|IN88US=>	NEDBd4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SKG-IIIa	NGTLfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXTrdFdvUUN3ME23MlgyQDl{IN88US=>	MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCE-T	NGnkSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVnJR\|UxRTdwOEe3PFMh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Ca-Ski	NH3NbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIfxU4dKSzVyPUeuPVk{QDNizszN	NVjPPYpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COLO-684	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYXnb3VRUUN3ME24MlAyQDF6IN88US=>	NGqwd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KYSE-70	MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVm0O4x4UUN3ME24MlA4PzJ7IN88US=>	MkTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TI-73	M2ruVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYjJR\|UxRThwMkW4OVEh\|ryP	NEGxV\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BT-20	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV;JR\|UxRThwMk[wOVIh\|ryP	MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MHH-ES-1	M{fzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn7wTWM2OD16LkWxPFM1KM7:TR?=	MmrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TE-12	NFXvV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mm[5TWM2OD16LkW5PVMyKM7:TR?=	NUHkW2VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
YH-13	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEfUWlVKSzVyPUiuOlExODhizszN	M2LS[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SF126	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlvzTWM2OD16LkizPFY2KM7:TR?=	NVnzb5o{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
J82	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3m0[2lEPTB;OD65NFA{QCEQvF2=	NFrWUG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RCC10RGB	NX3qWY1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX7Rc4JHUUN3ME24Mlk6PTZzIN88US=>	NVz6WVlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-UT-1	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnPmTWM2OD17LkC0PVQ2KM7:TR?=	MnjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	NGK1XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mlq2TWM2OD17LkG5NVM4KM7:TR?=	M3;oNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB996-RCC	M2j2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{[1bmlEPTB;OT6xPVg6KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EPLC-272H	MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1jnT2lEPTB;OT6zO\|Y2PyEQvF2=	M{PWPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CTV-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWfJR\|UxRTlwNU[1N\|Ih\|ryP	Mm\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HSC-2	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mmq2TWM2OD17LkW3OVUh\|ryP	NVTxOVhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-MEL-28	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXTJR\|UxRTlwNkG4PVMh\|ryP	NHjN[m09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MMAC-SF	NIPUVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MojYTWM2OD17Lk[4O\|Uh\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CP50-MEL-B	M2nsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4XZWWlEPTB;OT63OVc5OiEQvF2=	Ml32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HT-1080	M1m3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4rzUmlEPTB;OT63O\|c{QSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HEC-1	M4jo[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4f0Z2lEPTB;MUCuN\|M2OiEQvF2=	Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
AGS	NWfHWW13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1n0PWlEPTB;MUCuN\|c1KM7:TR?=	NVjJOlBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
GAMG	NVj5RoNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{TCcmlEPTB;MUCuOVE3OiEQvF2=	NX3FTnlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW48	NHixdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUjJR\|UxRTFyLkWxPFkh\|ryP	NULjem4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
U031	MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn;DTWM2OD1zMD61PVA5KM7:TR?=	NEXqSmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OVCAR-5	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoHKTWM2OD1zMD62OFI6KM7:TR?=	MnfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SF295	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn3oTWM2OD1zMD62O\|A1KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
BHT-101	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUDJR\|UxRTFyLkexO\|ch\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFrtSVRKSzVyPUGxMlMzODFizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ACHN	NVPOeI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3pTWM2OD1zMT60NlEyKM7:TR?=	MkHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H526	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnKcohuUUN3ME2xNU42ODR\|IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MN-60	NG\RRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUXJR\|UxRTFzLkWzPUDPxE1?	MkDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2291	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXvnV5ZrUUN3ME2xNU42PDZ4IN88US=>	NYW0OnFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SCC-25	NIX1XllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2ftZmlEPTB;MUGuO\|U2PiEQvF2=	M33yN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-MEL-2	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmjZTWM2OD1zMT63OlM4KM7:TR?=	NUXW[FlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SN12C	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkXDTWM2OD1zMT65N\|U2KM7:TR?=	NYW5NZlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H69	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVfVOYp1UUN3ME2xNk41OjN2IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ME-180	M3\ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWDrT\|R5UUN3ME2xNk44ODV2IN88US=>	MlXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MC-IXC	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2q1ZWlEPTB;MUKuO\|UyQCEQvF2=	NX;DSHhwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2347	NWXDXoxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHQTWM2OD1zMj63OlE1KM7:TR?=	NUW2R\|hIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
M059J	NYm4VHVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYfJR\|UxRTF{Lke3Nlch\|ryP	NWC5NVZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
A2058	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEHnSnlKSzVyPUGyMlg3QDFizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	M1;mWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnLnTWM2OD1zMj64O\|g2KM7:TR?=	M3H1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Ca9-22	M{jLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7VUG5KSzVyPUGyMlk1PTFizszN	M1;YWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KNS-42	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlnMTWM2OD1zMj65PVg1KM7:TR?=	NWf6Z4x[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LoVo	NV\u[21lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHzqdoFKSzVyPUGzMlI{OTNizszN	NGP1dmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
AM-38	NV\rVpFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHfGdWhKSzVyPUGzMlI2PjZizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB5	NGLxTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYX6do5PUUN3ME2xN{4{PzV{IN88US=>	NWf4dI45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
L-363	NHjX[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NILtOJlKSzVyPUGzMlQxOzNizszN	NHvxVXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-MEL-30	NEX6NJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPtTYdKSzVyPUG0MlA3PDVizszN	M{HlOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1563	NVzCdFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm\kTWM2OD1zND62NFM6KM7:TR?=	M{f3W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2228	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1HFSGlEPTB;MUSuOlA4PyEQvF2=	MoLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MFM-223	NXPRPYViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;3U2lEPTB;MUWuNVgyOyEQvF2=	M2DpU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB831-BLC	NIXpOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWrJR\|UxRTF3LkK3Olch\|ryP	MkHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW872	NF;SWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NED0[VRKSzVyPUG1MlMxQDZizszN	M{XTcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H522	M17WZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWTKd3lXUUN3ME2xOU4{OzB4IN88US=>	Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-1	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV7JR\|UxRTF3LkW0OlIh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HN	MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHHsSYpKSzVyPUG1MlU6PDJizszN	NH\wRoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW837	M4DLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUHJR\|UxRTF3Lke4OFch\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SCC-9	M4jIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fuWGlEPTB;MUWuPFEyPCEQvF2=	MlTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MKN7	NVLPfWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NILzclNKSzVyPUG1Mlk4OzJizszN	M1rYTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-410	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3PIb2lEPTB;MU[uOVkyKM7:TR?=	NU\tVYRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-N-DZ	M1WxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWjJR\|UxRTF4Lk[xNVYh\|ryP	NY[zU2hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COR-L105	NXrnWWJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M37FbGlEPTB;MU[uOlUzQCEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LB2518-MEL	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWTJR\|UxRTF4LkizPFkh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OVCAR-4	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlnRTWM2OD1zNj64PFYzKM7:TR?=	MnHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TK10	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVrJR\|UxRTF4Lkm0O\|Mh\|ryP	NVjX[YVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KNS-62	NVi0cGoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPzN4JSUUN3ME2xOk46Pzd5IN88US=>	NYm0dlFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RPMI-8866	NEDHUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml[1TWM2OD1zNz6xO\|MzKM7:TR?=	NXXuXZRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HuP-T4	NHXlZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVTJR\|UxRTF5LkK0PVUh\|ryP	Mki2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	NHy5O21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnHCTWM2OD1zNz61NlE6KM7:TR?=	NWDuXoZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
T-24	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LSNmlEPTB;MUeuOVM1PyEQvF2=	M{X2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HT-3	M1[2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVvqd2pkUUN3ME2xO{42QTF2IN88US=>	NHX5d4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KS-1	NEfwe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1yxWmlEPTB;MUeuOlc{KM7:TR?=	NHn0cYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1792	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmrTTWM2OD1zNz63PVgh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ABC-1	M1i3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoHPTWM2OD1zNz64NVQyKM7:TR?=	NFPsOJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BPH-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3jlcGlEPTB;MUiuNVY5PSEQvF2=	M4DDflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A431	NUnMbW1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEjUcW1KSzVyPUG4MlQyOjdizszN	M3qzTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
T98G	M3Lpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUHRUpRRUUN3ME2xPE42OTV5IN88US=>	NX3o[3pGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BHY	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmTrTWM2OD1zOD64Olkh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Capan-2	M4nGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYPJR\|UxRTF6LkmwO\|gh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MDA-MB-175-VII	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm\zTWM2OD1zOD65NlA6KM7:TR?=	NF2wcZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAL-27	M{PHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVKzZ2hJUUN3ME2xPU4xPDh5IN88US=>	NI\zbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
AsPC-1	M4jvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYi4dmVsUUN3ME2xPU45PjV5IN88US=>	M{DQeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KU812	Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M124WmlEPTB;MUmuPVU4OyEQvF2=	NXexOlNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H441	MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWXJR\|UxRTJyLkCwNUDPxE1?	M2WxTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Mewo	Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MULJR\|UxRTJyLkGyPFgh\|ryP	MojDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	M2\xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1j3emlEPTB;MkCuNVQ4PyEQvF2=	MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H727	NWXhbWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF2yS3VKSzVyPUKwMlI4ODRizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EKVX	NIrmRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2jHdmlEPTB;MkCuOlA3KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RT-112	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVnJR\|UxRTJyLk[xNlIh\|ryP	MlXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CAMA-1	NHLtXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1XGOWlEPTB;MkCuPVgxOyEQvF2=	NEmzOJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW900	NFrPRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVvNVZN7UUN3ME2yNU4xOTR7IN88US=>	M2LkZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H23	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHzMbJVKSzVyPUKxMlEzPzdizszN	NH\mVFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-PN-DW	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGXaRlBKSzVyPUKxMlE3PDlizszN	NXq0dJdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BB30-HNC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2rQe2lEPTB;MkGuNlc1PSEQvF2=	MmfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mle4TWM2OD1{MT6zOVM3KM7:TR?=	NETvS5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
IST-MEL1	NYfmcZlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXLJR\|UxRTJzLkO2PVIh\|ryP	NIXRb2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CTB-1	M4TCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mm\3TWM2OD1{MT60O\|U2KM7:TR?=	NFjiOIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LCLC-103H	NYDVTI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4Dm[mlEPTB;MkKuNVU5OiEQvF2=	NXnyTHZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PANC-03-27	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnjTTWM2OD1{Mj61NVY6KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HTC-C3	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmDXTWM2OD1{Mj61OVU2KM7:TR?=	NHzWOoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TE-8	NXuw[pN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVPJR\|UxRTJ\|LkK1OlUh\|ryP	M4jYVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H292	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmXsTWM2OD1{NT6zOVM3KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
COLO-680N	NH7RNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIjXPXpKSzVyPUK1MlY{OjlizszN	NH7seIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KYSE-520	M4XrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVnJR\|UxRTJ3Lk[0OEDPxE1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB10	M{O1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NG\VR3hKSzVyPUK2MlMyOTdizszN	NIjhRVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H661	M2XxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVnOZpVPUUN3ME2yOk41PzF\|IN88US=>	NHzQNow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GMS-10	NVezTYI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXTLU2M2UUN3ME2yOk45PjN6IN88US=>	M3S3PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2122	M3;obmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M170bGlEPTB;Mk[uPVk6QCEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OVCAR-8	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXjJR\|UxRTJ5LkC2N\|gh\|ryP	NYWyfJRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DJM-1	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnLiTWM2OD1{Nz6xOFU1KM7:TR?=	M1viTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
UACC-893	NWTHN4RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDlTWM2OD1{Nz65PFc5KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
C8166	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmfOTWM2OD1{OD62PVM5KM7:TR?=	NF\mNXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1693	M4DQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mnr0TWM2OD1{OD62PVc2KM7:TR?=	NGXKSIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TYK-nu	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF[0NVJKSzVyPUOwMlA{PDVizszN	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW1710	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4DHdWlEPTB;M{CuNVI3KM7:TR?=	M3S3d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A375	M2Pobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlP5TWM2OD1\|MD6zNlQ{KM7:TR?=	M{CzXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HMV-II	NVjtPINWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4rXd2lEPTB;M{GuN\|U6OiEQvF2=	MoDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2087	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGD0XIhKSzVyPUOxMlY{PTJizszN	NF7iZXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAL-54	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2XvOGlEPTB;M{GuO\|I1OSEQvF2=	M4K2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC70	NH7M[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVzJR\|UxRTN{LkGzPFch\|ryP	NU\xcVY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3ONVZKSzVyPUOyMlMxPjJizszN	M3nMVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1355	NIHN[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MofnTWM2OD1\|Mz6yNFQh\|ryP	MnfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CFPAC-1	Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUfJR\|UxRTN\|LkKzN\|Ih\|ryP	NHjzZnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MKN28	MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWHnNVMzUUN3ME2zN{4{QDB7IN88US=>	NH24T489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HDLM-2	NWGzboVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTN\|Lk[5N\|Eh\|ryP	MmXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
PANC-10-05	NHPHXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnjUTWM2OD1\|ND6xNFE1KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SAS	Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWPJR\|UxRTN2LkS1OlUh\|ryP	M2XRXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC1395	NIWweGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{D2eWlEPTB;M{SuO\|E5PiEQvF2=	NIi4SWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
8305C	NXTFRnFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M13IZWlEPTB;M{WuPFQyPSEQvF2=	Mn3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KM12	NEDzVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlnOTWM2OD1\|Nj63OVQ4KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1116	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmG1TWM2OD1\|Nz61PVkzKM7:TR?=	M4rMPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-MEL-1	NFrVOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYfob4d{UUN3ME2zPE4{Ozh7IN88US=>	MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC2218	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXPvd2M3UUN3ME2zPE43PTF7IN88US=>	NGnXPWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
T84	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGrWfFVKSzVyPUO4Mlc1ODlizszN	MkXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ETK-1	M4fkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn;RTWM2OD1\|OT6wNlIh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
COLO-800	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3nYfmlEPTB;M{muN\|g3QCEQvF2=	NXvZPHRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CAL-12T	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEfFUZdKSzVyPUO5MlUzQDFizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ACN	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYTD[4F5UUN3ME20NE41QTFzIN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SJSA-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWe5blRFUUN3ME20NU4yPTl4IN88US=>	M2fIeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
PSN1	NXzKUJlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDzTWM2OD12MT6xO\|Q6KM7:TR?=	MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
D-566MG	M4fOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYfQZWN{UUN3ME20NU4zODh4IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EGI-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4myb2lEPTB;NEKuOFI5KM7:TR?=	NGXOZ4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
A204	M4f0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVrJR\|UxRTR{Lk[zPFgh\|ryP	NYfRZVNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
Saos-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MU\JR\|UxRTR{LkizOlkh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SNU-C2B	NFrF[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1i3WWlEPTB;NEOuOlg4QCEQvF2=	Ml70QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HLE	NWexN2djT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkPvTWM2OD12ND6wPFU3KM7:TR?=	NHzBd5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW1463	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXSxSJNuUUN3ME20OE46QTdzIN88US=>	NEK1elM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DSH1	NXXqVIlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{ntOWlEPTB;NEWuNFA{OyEQvF2=	Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MCF7	NHTPdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml76TWM2OD12NT61NFUyKM7:TR?=	MlnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
K5	NGPuWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIfO[lZKSzVyPUS1Mlk1ODVizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H358	NGLKcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mmm4TWM2OD12Nz6yNVUh\|ryP	Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2030	M{O4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGXXOFRKSzVyPUS3MlI{PzRizszN	MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW948	NGW5UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4T3dWlEPTB;NEeuOFY1KM7:TR?=	NFnUN2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BALL-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX;kNWZwUUN3ME20O{43OTZ6IN88US=>	NIjRToU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TE-9	M{nYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkHVTWM2OD12Nz65OVgyKM7:TR?=	NIjIS409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-N-FI	M3PHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWrlW5dEUUN3ME20PE4xOzV6IN88US=>	NUC3b2RsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KALS-1	NVn4W4p1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4nkPGlEPTB;NEiuNVI5QSEQvF2=	NWXYZ3RCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HO-1-N-1	M2r2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2rKPWlEPTB;NEiuO\|Q1PSEQvF2=	NVPoU3VKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2452	NGrxS\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3frTWlEPTB;NEmuNVE2OiEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OC-314	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX3DbJVrUUN3ME20PU43QDN2IN88US=>	NGrIWWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

体内研究

用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验： ^[1]	- 合并 Cell lines: SCLC 细胞系 Concentrations: 0-1 μM Incubation Time: 48小时 Method: 人类肿瘤细胞系在37^oC 含5% CO₂环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠 Dosages: 100 mg/kg/d Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Navitoclax (ABT-263) SDF

分子量	974.61
化学式	C₄₇H₅₅ClF₃N₅O₆S₃
CAS号	923564-51-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
回答：
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
问题 2：
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
回答：
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
最新的Bcl-2家族激活剂

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
经典的Bcl-2抑制剂

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

研究领域

产品类型

定制您的化合物库

Navitoclax (ABT-263)

客户使用Selleck生产的Navitoclax (ABT-263)发表文献237篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Navitoclax (ABT-263) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品